Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Eur Rev Med Pharmacol Sci ; 27(18): 8754-8761, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37782187

ABSTRACT

OBJECTIVE: Obese people are at increased risk of arrhythmia and sudden death, even in the absence of heart dysfunction. Increased insulin resistance, neurohumoral and autonomic changes in obesity can cause atrial and ventricular repolarization abnormalities. This study aimed to investigate the effect on ventricular repolarization parameters and to show the increased risk of ventricular arrhythmia in obese children. PATIENTS AND METHODS: The data of 50 obese children aged 2-18 who applied to the Pediatric Endocrinology Outpatient Clinic were evaluated prospectively. In 12-lead ECGs, heart rate, Pmax, Pmin, P-wave dispersion (Pwdisp), QTmax, QTmin, QT dispersion (QTd), QTcmax, QTcmin, QTc interval dispersion (QTcd), Tpeak-Tend interval (Tp-e), Tp-e/QT, Tp-e/QTc were calculated electronically. RESULTS: Tp-e time (0.041 ± 0.004/0.049 ± 0.015/p=0.018) and Tp parameters were measured in obese children with and without insulin resistance. Tp-e/QT ratio was also found to be high (p=0.035). There is a negative correlation between BMI SDS values and QTcmax and QTcmin values in patients with insulin resistance (p=0.015). CONCLUSIONS: In our study, the Tp-e interval and Tp-e/QT ratios, which had been revealed in literature to be more sensitive in demonstrating ventricular arrhythmias, were found to be higher in obese individuals with insulin resistance than in those without insulin resistance. Obese individuals with or without insulin resistance should be carefully evaluated in terms of atrial and ventricular depolarization and repolarization parameters with 12-lead ECG during their outpatient controls, and annual 24-hour Holter control should be performed to detect arrhythmias.


Subject(s)
Atrial Fibrillation , Insulin Resistance , Pediatric Obesity , Humans , Child , Electrocardiography
2.
Eur Rev Med Pharmacol Sci ; 27(9): 4053-4059, 2023 05.
Article in English | MEDLINE | ID: mdl-37203829

ABSTRACT

OBJECTIVE: Transcatheter closure of medium and large ventricular septal defects (VSDs) in young children is limited due to the use of over-sized devices that can cause hemodynamic instability and arrhythmia. In this study, we aimed to retrospectively evaluate the safety and efficacy of the device in the mid-term in children weighing less than 10 kg whose transcatheter VSD was closed only with the Konar-MFO device. PATIENTS AND METHODS: Among 70 children whose transcatheter VSD was closed between January 2018 and January 2023, 23 patients weighing less than 10 kg were included in the study. Retrospectively, the medical records of all patients were reviewed. RESULTS: The mean age of the patients was 7.3 (4.5-26) months. 17 of the patients were females, 6 of them were males, F/M: 2.83. The average weight was 6.1 (3.7-9.9) kg. The mean the pulmonary blood flow/ systemic blood flow (Qp/Qs) was 3.3 (1.7-5.5). The mean defect diameter was 7.8 mm (5.7-11) for the left ventricle (LV) side, and 5.7 mm (3-9.3) for the right ventricle (RV) side. Based on the utilized device dimensions, the measurements on the LV side were recorded as 8.6 mm (range 6-12), while those on the RV side were recorded as 6.6 mm (range 4-10). Antegrade technique was applied to 15 (65.2%) patients and retrograde technique was applied to 8 (34.8%) patients in the closure procedure. The procedure success rate was 100%. The incidence of death, device embolization, hemolysis, or infective endocarditis was zero. CONCLUSIONS: Perimembranous and muscular VSDs in children under 10 kg can be successfully closed under the management of an experienced operator with the Lifetech Konar-MFO device. This is the first study in the literature to evaluate the efficacy and safety of the device in children under 10 kg in whom only Konar-MFO VSD occluder device is used for transcatheter VSD closure.


Subject(s)
Cardiac Catheterization , Heart Septal Defects, Ventricular , Male , Female , Humans , Child , Child, Preschool , Infant , Retrospective Studies , Treatment Outcome , Cardiac Catheterization/methods , Arrhythmias, Cardiac , Heart Septal Defects, Ventricular/surgery
3.
Int J Lab Hematol ; 38(5): 569-75, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27435353

ABSTRACT

INTRODUCTION: In this study, we aimed to evaluate Red blood cell distribution width (RDW) in patients with acute rheumatic carditis during the acute phase and after anti-inflammatory therapy. METHODS: Pediatric patients diagnosed with acute rheumatic carditis (ARC) between 2006 and 2014 and age- and sex-matched controls were retrospectively analyzed. At the time of diagnosis and after 2 months of medical therapy, we reviewed the obtained demographic features; echocardiographic data; complete blood count reports, including RDW; acute phase reactants, including C-reactive protein; and erythrocyte sedimentation rate values. RESULTS: The number of the cases with ARC and age- and sex-matched controls were 100 and 110, respectively. The mean age of patients was 11.6 ± 2.5 years. WBC and platelet counts, RDW were found to be significantly higher in patient group compared with controls at the time of diagnosis, prior to the onset of treatment. RDW, platelet count, CRP, and ESR levels significantly decreased after an 8 weeks of medical treatment. RDW values after the medical treatment were still significantly higher compared with controls. RDW values were significantly higher in patients with multiple valvular involvement both prior to and after the treatment. Moreover, we found a significant and positive correlation between the RDW and the severity of mitral regurgitation in our patients (r: 0.46, P < 0.001). CONCLUSIONS: High levels of RDW after initial medical treatment may indicate an ongoing subtle inflammatory process that leads to future stenotic valvular lesions. However, long-term follow-up studies are needed involving adulthood period to support this hypothesis.


Subject(s)
Erythrocyte Indices , Mitral Valve Insufficiency/blood , Rheumatic Heart Disease/blood , Adolescent , Biomarkers/blood , Child , Female , Humans , Leukocyte Count , Male , Mitral Valve Insufficiency/etiology , Platelet Count , Predictive Value of Tests , Retrospective Studies , Rheumatic Heart Disease/complications
4.
Bratisl Lek Listy ; 115(9): 538-43, 2014.
Article in English | MEDLINE | ID: mdl-25318911

ABSTRACT

BACKGROUND: Cardiac contusion is an important cause of mortality after blunt chest trauma (BCT). The aim of this study was to investigate the therapeutic efficacy of the usage of aminoguanidine (AG), in myocardial damage occurring after BCT, alone and in combination with methylprednisolone (MP). METHODS: Thirty-five female Wistar albino rats were randomly assigned to five groups (n = 7) including: sham controls (S); only cardiac contusion (CONT); cardiac contusion treated with methylprednisolone (CONT+MP); cardiac contusion treated with aminoguanidine (CONT+AG); and cardiac contusion treated with methylprednisolone and aminoguanidine (CONT+MP+AG). Seven days following the treatments, heart and serum specimens were evaluated histopathologically, immunohistochemically, and biochemically in all groups. RESULTS: Serum AOPP and Tn-I levels increased significantly after cardiac contusions. Haemorrhage, tissue degeneration, and necrosis development was evident following contusions. Increased iNOS expression in myocardial tissue was significantly decreased in the CONT+AG+MP group compared to CONT+AG and CONT+MP groups (p = 0.001 and p = 0.011, respectively). The combined treatment of AG and MP increased Bcl-2 expression significantly after contusions compared to the other treatment groups. CONCLUSIONS: Combined usage of AG, a selective iNOS inhibitor, with MP, in cardiac contusions, showed a more powerful cardioprotective effect by increasing Bcl-2 expression and reducing iNOS expression (Tab. 3, Fig. 4, Ref. 33).


Subject(s)
Contusions/drug therapy , Enzyme Inhibitors/therapeutic use , Glucocorticoids/therapeutic use , Guanidines/therapeutic use , Heart Injuries/drug therapy , Methylprednisolone/therapeutic use , Animals , Drug Therapy, Combination , Female , Nitric Oxide Synthase Type II/antagonists & inhibitors , Rats, Wistar
5.
Indian J Med Microbiol ; 32(4): 451-4, 2014.
Article in English | MEDLINE | ID: mdl-25297038

ABSTRACT

Acute rheumatic fever (ARF) carditis is treated with steroids, which can cause changes in the cellular immune response, especially decreased CD3 (+) T cells. Nosocomial infections due to steroid use for treatment of ARF carditis or secondary to the changes in the cellular immune response have not been reported in the literature. Sphingomonas paucimobilis is a Gram-negative bacillus causing community- and hospital-acquired infections. It has been reported as causing bacteraemia/sepsis, pneumonia or peritonitis in patients with malignancies, immunosuppression or diabetes. We present a case with S. paucimobilis bacteraemia/sepsis and shock after administration of steroids for treatment of ARF carditis. We suggest early identification of the causative agent and appropriate adjustments of the treatment plan to avoid shock and possible mortality. This is the first reported case of S. paucimobilis bacteraemia/sepsis in the setting of steroid use for ARF carditis.


Subject(s)
Anti-Inflammatory Agents/adverse effects , Gram-Negative Bacterial Infections/diagnosis , Rheumatic Heart Disease/complications , Shock, Septic/diagnosis , Shock, Septic/pathology , Sphingomonas/isolation & purification , Steroids/adverse effects , Adolescent , Anti-Inflammatory Agents/therapeutic use , Antigens, CD/analysis , Echocardiography , Female , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/pathology , Humans , Lymphocyte Subsets/immunology , Radiography, Thoracic , Rheumatic Heart Disease/drug therapy , Shock, Septic/microbiology , Sphingomonas/classification , Steroids/therapeutic use
6.
Braz. j. med. biol. res ; 47(9): 766-772, 09/2014. tab, graf
Article in English | LILACS | ID: lil-719315

ABSTRACT

Cardiac contusion is a potentially fatal complication of blunt chest trauma. The effects of a combination of quercetin and methylprednisolone against trauma-induced cardiac contusion were studied. Thirty-five female Sprague-Dawley rats were divided into five groups (n=7) as follows: sham, cardiac contusion with no therapy, treated with methylprednisolone (30 mg/kg on the first day, and 3 mg/kg on the following days), treated with quercetin (50 mg·kg−1·day−1), and treated with a combination of methylprednisolone and quercetin. Serum troponin I (Tn-I) and tumor necrosis factor-alpha (TNF-α) levels and cardiac histopathological findings were evaluated. Tn-I and TNF-α levels were elevated after contusion (P=0.001 and P=0.001). Seven days later, Tn-I and TNF-α levels decreased in the rats treated with methylprednisolone, quercetin, and the combination of methylprednisolone and quercetin compared to the rats without therapy, but a statistical significance was found only with the combination therapy (P=0.001 and P=0.011, respectively). Histopathological degeneration and necrosis scores were statistically lower in the methylprednisolone and quercetin combination group compared to the group treated only with methylprednisolone (P=0.017 and P=0.007, respectively). However, only degeneration scores were lower in the combination therapy group compared to the group treated only with quercetin (P=0.017). Inducible nitric oxide synthase positivity scores were decreased in all treatment groups compared to the untreated groups (P=0.097, P=0.026, and P=0.004, respectively). We conclude that a combination of quercetin and methylprednisolone can be used for the specific treatment of cardiac contusion.


Subject(s)
Animals , Female , Contusions/drug therapy , Heart Injuries/drug therapy , Methylprednisolone/therapeutic use , Myocardium/pathology , Quercetin/therapeutic use , Wounds, Nonpenetrating/complications , Anti-Inflammatory Agents/therapeutic use , Antioxidants/therapeutic use , Contusions/etiology , Drug Therapy, Combination , Heart Injuries/etiology , Immunohistochemistry , Necrosis , Nitric Oxide Synthase Type II/isolation & purification , Rats, Sprague-Dawley , Thoracic Injuries/complications , Troponin I/blood , Tumor Necrosis Factor-alpha/blood
7.
Braz J Med Biol Res ; 47(9): 766-72, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25098616

ABSTRACT

Cardiac contusion is a potentially fatal complication of blunt chest trauma. The effects of a combination of quercetin and methylprednisolone against trauma-induced cardiac contusion were studied. Thirty-five female Sprague-Dawley rats were divided into five groups (n=7) as follows: sham, cardiac contusion with no therapy, treated with methylprednisolone (30 mg/kg on the first day, and 3 mg/kg on the following days), treated with quercetin (50 mg·kg(-1)·day(-1)), and treated with a combination of methylprednisolone and quercetin. Serum troponin I (Tn-I) and tumor necrosis factor-alpha (TNF-α) levels and cardiac histopathological findings were evaluated. Tn-I and TNF-α levels were elevated after contusion (P=0.001 and P=0.001). Seven days later, Tn-I and TNF-α levels decreased in the rats treated with methylprednisolone, quercetin, and the combination of methylprednisolone and quercetin compared to the rats without therapy, but a statistical significance was found only with the combination therapy (P=0.001 and P=0.011, respectively). Histopathological degeneration and necrosis scores were statistically lower in the methylprednisolone and quercetin combination group compared to the group treated only with methylprednisolone (P=0.017 and P=0.007, respectively). However, only degeneration scores were lower in the combination therapy group compared to the group treated only with quercetin (P=0.017). Inducible nitric oxide synthase positivity scores were decreased in all treatment groups compared to the untreated groups (P=0.097, P=0.026, and P=0.004, respectively). We conclude that a combination of quercetin and methylprednisolone can be used for the specific treatment of cardiac contusion.


Subject(s)
Contusions/drug therapy , Heart Injuries/drug therapy , Methylprednisolone/therapeutic use , Myocardium/pathology , Quercetin/therapeutic use , Wounds, Nonpenetrating/complications , Animals , Anti-Inflammatory Agents/therapeutic use , Antioxidants/therapeutic use , Contusions/etiology , Drug Therapy, Combination , Female , Heart Injuries/etiology , Immunohistochemistry , Necrosis , Nitric Oxide Synthase Type II/isolation & purification , Rats, Sprague-Dawley , Thoracic Injuries/complications , Troponin I/blood , Tumor Necrosis Factor-alpha/blood
9.
J BUON ; 18(1): 261-7, 2013.
Article in English | MEDLINE | ID: mdl-23613414

ABSTRACT

PURPOSE: Treating cancer often involves the use of chemotherapeutic agents. Due to the growing incidence of cancer worldwide and the expanding number of treatment options, it is important to understand the risks of adverse events associated with these treatments. In this study, we monitored the occurrence of acute infusion reactions in an outpatient chemotherapy center from April 2011 to April 2012. METHODS: For patients who developed infusion reactions, the causative drug, the dose and number of treatments received, the onset time of the reaction, the duration of the reaction, blood pressure, pulse, level of oxygen saturation during the reaction, and other symptoms were recorded. The severity of reactions was determined in accordance with NCI toxicity criteria. A reaction was considered as grade 1-2 (mild-moderate) if the patient experienced flushing, rash, fever, tremor, dyspnea, rigor, and mild hypotension. Symptoms such as severe hypotension, bronchospasm, cardiac dysfunction and anaphylaxis, requiring therapeutic intervention, were classified as severe, grade 3-4 reactions. RESULTS: Of the 2213 patients receiving chemotherapy during the study period, 138 (62%) developed an infusion reaction to the treatment. Among 138 patients most commonly treated types of carcinoma included breast (39.2%), lung (17.8%), colorectal (10%), and ovarian (8.5%) cancers. Docetaxel administration resulted in the largest number of infusion reactions, though most reactions were mild to moderate and did not require the cessation of treatment. Patients with mild to moderate reactions (89.2%) were able to continue treatment, while those who developed severe reactions (10.8%) could not continue treatment with the same agent. CONCLUSION: Although severe reactions are rare, the incidence of mild to moderate reactions against taxanes, platinum compounds, and monoclonal antibodies is quite high. Clinical symptoms do not vary widely among the agents, though the onset time of symptoms does vary. While reactions against platinum agents were of type 1 anaphylactic reactions, reactions against taxanes and monoclonal antibodies during the first infusion and in the following minutes suggest the activation of different mechanisms.


Subject(s)
Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Drug Hypersensitivity/etiology , Drug-Related Side Effects and Adverse Reactions/chemically induced , Acute Disease , Adult , Aged , Ambulatory Care , Drug Hypersensitivity/diagnosis , Drug Hypersensitivity/epidemiology , Drug-Related Side Effects and Adverse Reactions/diagnosis , Drug-Related Side Effects and Adverse Reactions/epidemiology , Female , Humans , Incidence , Infusions, Parenteral , Male , Middle Aged , Prognosis , Risk Factors , Severity of Illness Index , Time Factors , Turkey/epidemiology
10.
Case Rep Oncol ; 5(2): 275-9, 2012 May.
Article in English | MEDLINE | ID: mdl-22740816

ABSTRACT

PURPOSE: To present a case of spontaneous aortic rupture in the course of mantle cell lymphoma and successful management with endovascular repair. CASE REPORT: A 69-year-old woman presented with a cervical mass. The patient was found to have stage IIIA and Mantle Cell Lymphoma International Prognostic Index (MIPI) 4. She was placed in an intermediate-risk group. The patient received an initial cycle of systemic chemotherapy consisting of rituximab, anthracycline, vincristine and methyl prednisolone. During follow-up, she developed abdominal aortic rupture secondary to intramural hematoma which was successfully managed with endovascular exclusion. CONCLUSION: Hemodynamic changes can be seen during the course of lymphoma subsequent to systemic chemotherapy. These changes might be related to the spontaneous rupture of the main vessels. Endovascular repair may be a more appropriate treatment option than open surgery, especially in a patient with multiple comorbidities.

11.
J BUON ; 16(3): 469-72, 2011.
Article in English | MEDLINE | ID: mdl-22006752

ABSTRACT

PURPOSE: The purpose of this study was to report the clinical course and outcome of patients suffering from advanced cholangiocarcinoma (CCA). METHODS: The medical records of 93 patients with unresectable or metastatic CCA were retrospectively analyzed. RESULTS: Out of 93 patients, 53 (64.9%) were initially managed with palliative biliary drainage (PBD). Cisplatinbased regimens were administered to 18 (19.3%) patients, and non-cisplatin regimens (mainly 5-fluorouracil [5-FU]- based) were administered to 23 (24.8%) patients. Of all 93 patients 53 (55.9%) did not receive chemotherapy. The median overall survival (OS) for all patients was 6.1 months and was significantly higher in patients treated with chemotherapy as compared to those without chemotherapy (p=0.002). However, no difference in OS was seen in patients treated with cisplatin- or 5-FU-based chemotherapy. We noticed that a high number of patients were not referred to a medical oncologist even for advice. CONCLUSION: The relief of bile duct obstruction is an important part of the initial patient management. One of the main observations of this study was that systemic chemotherapy significantly improved survival. Increased awareness of the medical oncologists' role in the management of CCA can increase the number of patients who can have access to chemotherapy.


Subject(s)
Bile Duct Neoplasms/drug therapy , Bile Ducts, Intrahepatic , Cholangiocarcinoma/drug therapy , Adult , Aged , Aged, 80 and over , Bile Duct Neoplasms/mortality , Cholangiocarcinoma/mortality , Female , Humans , Male , Middle Aged
14.
J Child Neurol ; 15(11): 765-7, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11108514

ABSTRACT

We present a 4-year-old girl with neurofibromatosis-1 who developed moyamoya syndrome characterized by bilateral stenosis or occlusion of the distal internal carotid arteries and their branches, leading to the development of an abnormal vascular network. In light of a literature review, the postradiation vasculopathy of the moyamoya type and its relationship with neurofibromatosis-1 are discussed.


Subject(s)
Abnormalities, Radiation-Induced , Moyamoya Disease/etiology , Neurofibromatosis 1/complications , Optic Nerve Glioma/radiotherapy , Abnormalities, Radiation-Induced/diagnostic imaging , Abnormalities, Radiation-Induced/physiopathology , Age Factors , Cerebrovascular Circulation , Child, Preschool , Female , Humans , Magnetic Resonance Angiography , Moyamoya Disease/diagnostic imaging , Moyamoya Disease/physiopathology , Neurofibromatosis 1/physiopathology , Optic Nerve Glioma/etiology , Radiography
15.
Pediatr Hematol Oncol ; 17(8): 695-9, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11127402

ABSTRACT

A case of primary pleural non-Hodgkin lymphoma in a 2.5-year-old girl is reported. The patient had pleural involvement as the initial and only manifestation of the disease. Histopathologic examination showed lymphoblastic lymphoma of T-cell origin. The child received the modified LSA2-L2 protocol. During the maintenance treatment, she had an isolated central nervous system relapse and died of neutropenic sepsis. To the authors' knowledge this represents the first case report of primary pleural lymphoma in the childhood period.


Subject(s)
Lymphoma, T-Cell/diagnosis , Pleural Effusion, Malignant/diagnosis , Child, Preschool , Fatal Outcome , Female , Humans , Lymphoma, T-Cell/diagnostic imaging , Lymphoma, T-Cell/pathology , Pleural Effusion, Malignant/diagnostic imaging , Pleural Effusion, Malignant/pathology , Tomography, X-Ray Computed
16.
Pediatr Hematol Oncol ; 17(7): 585-90, 2000.
Article in English | MEDLINE | ID: mdl-11033734

ABSTRACT

Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects. Most studies report incidence rates ranging from 1.5 to 3%. There is no study on the incidence rate among children with systemic malignancies. Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.


Subject(s)
Cilastatin/adverse effects , Imipenem/adverse effects , Neoplasms/complications , Protease Inhibitors/adverse effects , Seizures/chemically induced , Thienamycins/adverse effects , Adolescent , Child , Cilastatin/therapeutic use , Cilastatin, Imipenem Drug Combination , Drug Combinations , Female , Fever/drug therapy , Fever/etiology , Humans , Imipenem/therapeutic use , Neutropenia/complications , Protease Inhibitors/therapeutic use , Thienamycins/therapeutic use
17.
Pediatr Hematol Oncol ; 16(6): 525-31, 1999.
Article in English | MEDLINE | ID: mdl-10599092

ABSTRACT

This prospective study evaluated 382 pediatric patients with peripheral lymphadenopathy (LA) presenting at the Pediatric Oncology and Hematology Departments of Social Security Children's Hospital and Gazi University Medical Faculty Hospital. The ages of the patients ranged between 2 months and 16 years (median 7 years); 72% of the patients were male. Of the 382 patients, 138 had localized LA (a single anatomic area involved), 171 had limited LA (two or three areas involved), and 73 had generalized LA (four or more anatomic areas involved). The specific etiology (either benign or malign) was defined in 79% of patients with generalized LA. However, in patients with localized LA and limited LA, specific etiology could be identified only in 43 and 53% of patients, respectively. Based on this study, BCG-LA and pyogenic infections are more frequently manifested by localized LA; LA of unknown origin, Hodgkin's disease, tuberculosis, nasopharyngeal carcinoma, and toxoplasmosis are frequently manifested by localized or limited LA; and cytomegalovirus infection (CMV), infectious mononucleous, rubella, acute leukemia, non-Hodgkin's lymphoma are frequently manifested by limited or generalized LA. Out of 382 patients, 196 patients had a maximum lymph node diameter of less than 2 cm. A benign etiology was shown in 159/196 of these patients. In 37/196 of these patients LA was due to a malignancy, and these cases almost invariably had some apparent additional diagnostic clinical and laboratory findings. Based on this observation a maximum lymph node size of 2 cm was considered an appropriate limit to distinguish malignant disease from benign causes except when there is other evidence of an underlying malignant disease. However, lymphadenopathies located at supraclavicular region (27 patients) either localized or as part of generalized LA had a specific benign or malignant disease in etiology (malignancy in 20, tuberculosis in 3, CMV in 2, sarcoidosis in 1, and lipoma in 1) even though they were less than 2 cm in diameter.


Subject(s)
Lymphatic Diseases/etiology , Adolescent , Child , Child, Preschool , Cohort Studies , Female , Humans , Infant , Lymph Nodes/pathology , Lymphatic Diseases/epidemiology , Lymphoma/complications , Lymphoma/diagnosis , Male , Prospective Studies , Time Factors , Tuberculosis, Lymph Node/complications , Tuberculosis, Lymph Node/diagnosis , Turkey/epidemiology
18.
Article in English | MEDLINE | ID: mdl-10102592

ABSTRACT

OBJECTIVE: The purpose of this study was to evaluate the effects of chemotherapy on oral and dental structures and craniofacial growth in 30 survivors of childhood lymphoma. STUDY DESIGN: Eruption status, root malformations, premature apexification, agenesis, crown anomalies, soft tissue abnormalities, gingival and periodontal status, enamel defects and discolorations, and craniofacial growth status of the subjects were documented and compared with findings in 20 healthy children who served as controls. RESULTS: Statistically significant (P < .05) differences between the study and control groups were found for plaque index, enamel hypoplasias, discolorations, and agenesis. CONCLUSIONS: The results of the study suggest that antineoplastic therapy and/or childhood cancer can result in a higher prevalence of various malformations in teeth. Children treated in the early years of their lives displayed the most severe dental defects, suggesting that immature teeth are at a greater risk of developmental disturbances than fully developed teeth.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Lymphoma/drug therapy , Maxillofacial Development/drug effects , Tooth Abnormalities/chemically induced , Tooth Eruption/drug effects , Adolescent , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Asparaginase/administration & dosage , Asparaginase/adverse effects , Bleomycin/administration & dosage , Bleomycin/adverse effects , Case-Control Studies , Child , Child, Preschool , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , DMF Index , Dacarbazine/administration & dosage , Dacarbazine/adverse effects , Daunorubicin/administration & dosage , Daunorubicin/adverse effects , Dental Plaque Index , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Female , Humans , Male , Methotrexate/adverse effects , Periodontal Index , Prednisone/administration & dosage , Prednisone/adverse effects , Procarbazine/administration & dosage , Procarbazine/adverse effects , Remission Induction , Survivors , Vinblastine/administration & dosage , Vinblastine/adverse effects , Vincristine/administration & dosage , Vincristine/adverse effects
20.
Pediatr Hematol Oncol ; 16(1): 35-41, 1999.
Article in English | MEDLINE | ID: mdl-9932271

ABSTRACT

Malnutrition in children with cancer is reported to be relatively uncommon at the time of diagnosis. However, in most studies nutritional status measurement has relied almost exclusively on weight-related indices. This can be misleading, because in children with malignancy, tumor masses can reach more than 10% of total body weight. A controlled study was performed in 62 patients using arm anthropometry to provide a more accurate evaluation of the nutritional status of children with cancer at presentation. Height, weight, midupper arm circumference (MUAC), and triceps skinfold thickness (TSFT) were measured in all patients (40 boys, 22 girls) and controls (18 boys, 13 girls). Weight for height (WFH) of each patient was compared with the national standards. MUAC and TSFT were also interpreted according to the standards developed by A. Roberto Frisancho. The mean ages were 6.5 +/- 3.7 years (range 0.08-13) and 5.7 +/- 4.7 years (range 0.25-15) in patients and control group, respectively. Results showed that although the WFH values for patients were normal, MUAC and TSFT values were significantly less than control values (P < 0.001). Moreover, 27% of patients showed malnutrition (they had MUAC and TSFT below 5th percentile). Patients with intraabdominal solid tumors had significantly lower MUAC and TSFT values than those with extraabdominal solid tumors (P < 0.05). The data strongly indicate that malnutrition is common at the time of diagnosis in children with cancer, and arm anthropometry should replace the use of weight-related indices to identify malnutrition in children.


Subject(s)
Arm , Neoplasms/physiopathology , Nutrition Disorders/etiology , Nutrition Disorders/physiopathology , Adolescent , Anthropometry/methods , Body Height , Body Weight , Child , Child, Preschool , Failure to Thrive/etiology , Female , Growth Disorders/etiology , Humans , Infant , Male , Neoplasm Staging , Neoplasms/pathology , Nutrition Disorders/diagnosis , Reference Values , Skinfold Thickness
SELECTION OF CITATIONS
SEARCH DETAIL
...